文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

真实世界数据网络中疫苗安全监测的快速周期分析框架:杨森COVID-19疫苗增强监测的经验

A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
PubMed 文献 · Vaccine · 2025-03-29

杨森在四个美国医疗索赔数据库中,采用三种疫苗暴露、56种结局和93个阴性对照的标准化算法,对杨森COVID-19疫苗进行近实时安全监测。13种结局超过预设发现阈值,吉兰-巴雷综合征(GBS)和贝尔麻痹信号最一致;GBS在1-28天风险窗的效应估计为自对照设计发病率比4.0(95%CI 2.1-7.7)至队列设计风险比6.3(95%CI 3.0-13.0)。

要点

  • 在四个美国医疗索赔数据库中开展快速周期分析,覆盖56种结局和93个阴性对照。
  • 13种结局超过预设发现阈值,GBS和贝尔麻痹信号在不同时间、方法和数据源中最一致。
  • GBS在1-28天风险窗的发病率比为4.0(95%CI 2.1-7.7),风险比为6.3(95%CI 3.0-13.0)。

核心结论

  • 本工作证明在多个数据库中采用互补方法、跨越连续时间点对众多结局进行快速周期分析的价值和可行性,同时保持科学完整性。
  • 该方法的可扩展性得益于预先指定分析诊断和相应阈值,从而排除可能产生不可靠结果的分析,最大限度减少主观解释和对失败诊断检验的事后合理化。

研究设计与样本

  • 杨森在四个美国医疗索赔数据库(2022年2月至2023年5月)中开展快速真实世界数据分析,用于杨森COVID-19疫苗的近实时安全监测。
  • 分析使用标准化算法,涵盖三种疫苗暴露、56种结局和93个阴性对照。
  • 研究进行了三项自身对照病例系列和两种比较队列变体,每种均考虑疫苗接种后多个风险期。
  • 仅通过预先确定的标准化诊断的结果才被揭盲。
  • 采用两种证据解释策略:发现策略旨在支持发现可能未知的关联以供进一步研究,并校正多重检验和随时间连续查看;估计策略旨在量化特定暴露-结局对的关联强度并评估统计不确定性。

主要发现

  • 共有13种关注结局的结果超过预设发现阈值。
  • 吉兰-巴雷综合征(GBS)和贝尔麻痹在不同时间、分析方法和数据源中信号最一致。
  • GBS于2021年8月被添加至产品信息作为药物不良反应,并被用作示例展示该快速分析框架的各个方面。
  • GBS的估计结果一致,1-28天风险窗的效应估计从自身对照设计的发病率比4.0(95%CI 2.1-7.7)到队列设计的风险比6.3(95%CI 3.0-13.0)。

关键数值与推荐

  • 发现策略校正多重检验和随时间连续查看。
  • 仅通过预先确定的标准化诊断的结果才被揭盲。
  • 13种关注结局超过预设发现阈值。
  • GBS在1-28天风险窗的自身对照设计发病率比为4.0(95%CI 2.1-7.7)。
  • GBS在1-28天风险窗的队列设计风险比为6.3(95%CI 3.0-13.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To complement and support routine pharmacovigilance, Janssen conducted rapid real-world data analyses for near real-time safety monitoring of the Janssen COVID-19 vaccine and to contextualize potential safety signals. METHODS: Analyses were performed in four U.S. healthcare claims databases (February 2022-May 2023) using standardized algorithms for three vaccine exposures, 56 outcomes, and 93 negative controls. Three self-controlled case series and two comparative cohort variants were conducted, each with consideration of multiple at-risk periods following vaccination. Only results that passed pre-determined, standardized diagnostics were unblinded. Two evidence interpretation strategies were employed: 1) Discovery: aimed to support discovering potentially unknown associations for further investigation, correcting for multiple testing and sequential looks over time. 2) Estimation: aimed to quantify the strength of association for specific exposure-outcome pairs and assess statistical uncertainty. RESULTS: A total of 13 outcomes of interest showed results exceeding the prespecified Discovery threshold. Guillain-Barré Syndrome (GBS) and Bell's palsy had the most consistent signaling over time, analytic methods, and data sources. GBS, an adverse drug reaction that was added to the product information in August 2021, is used as the example to demonstrate the aspects of this rapid analytic framework. Estimation results for GBS were consistent, with effect estimates in the 1-28 day risk window ranging from an incidence rate ratio of 4.0 (95 % confidence interval: 2.1-7.7) in a self-controlled design to a hazard ratio of 6.3 (3.0-13.0) in a cohort design. CONCLUSIONS: This work demonstrates the value and feasibility of conducting rapid cycle analysis across numerous outcomes in multiple databases employing complementary methodologies over successive time points while maintaining scientific integrity. The scalability of the approach is facilitated by the a priori specification of analytic diagnostics and corresponding thresholds, which excludes analyses likely to yield unreliable results, thereby minimizing subjective interpretation and post-hoc rationalization of failed diagnostic tests.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Newbern EC, Shoaibi A, Haynes K, et al. A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine. Vaccine. 2025. PMID: 40158304. doi:10.1016/j.vaccine.2025.127044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。